We are live on ! Find out more
SER icon

Serina Therapeutics
SER

25 hedge funds and large institutions have $1.6M invested in Serina Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.21% more ownership

Funds ownership: 3.38% → 3.59% (+0.21%)

0% more funds holding

Funds holding: 25 → 25 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

20% less capital invested

Capital invested by funds: $2.01M → $1.6M (-$408K)

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
4
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$104K
2
UBS Group
UBS Group
Switzerland
+$22.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.8K
4
TRCT
Tower Research Capital (TRC)
New York
+$1.21K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$27.8K
2
Osaic Holdings
Osaic Holdings
Arizona
-$30
3
DB
Danske Bank
Denmark
-$13
4
FCM
Fourpath Capital Management
Oklahoma
-$13
5
HighTower Advisors
HighTower Advisors
Illinois
-$6
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$427K – – –
WA
2
Waverly Advisors
Alabama
$338K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$311K +$104K +17,573 +39%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$131K +$12.8K +2,170 +9%
HighTower Advisors
5
HighTower Advisors
Illinois
$112K -$6 -1 -0%
KP
6
Keel Point
Alabama
$89K – – –
Northern Trust
7
Northern Trust
Illinois
$74.1K -$6 -1 -0%
Millennium Management
8
Millennium Management
New York
$72.9K -$27.8K -4,705 -24%
UBS Group
9
UBS Group
Switzerland
$19.1K +$22.5K +3,808 +380,800%
BlackRock
10
BlackRock
New York
$17.9K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$5.05K +$1.21K +205 +25%
SS
12
SBI Securities
Japan
$501 +$590 +100 New
PSB
13
Piscataqua Savings Bank
New Hampshire
$140 – – –
RAM
14
Riggs Asset Management
Pennsylvania
$121 – – –
Bank of America
15
Bank of America
North Carolina
$120 – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$65 – – –
AFG
17
Albion Financial Group
Utah
$41 – – –
Morgan Stanley
18
Morgan Stanley
New York
$40 – – –
PP
19
Pacifica Partners
Canada
$39 – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$25 -$30 -5 -50%
SIS
21
Strategic Investment Solutions
Illinois
$20 – – –
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$10 – – –
Wells Fargo
23
Wells Fargo
California
$10 – – –
AG
24
AmeriFlex Group
Nevada
$9 +$12 +2 New
TCOV
25
Trust Company of Vermont
Vermont
$5 – – –
1
2

SER Hedge Fund Activity: Q4 2024 in Review

25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q4 2024, worth a combined $1.6M — down 20% from $2.01M a quarter earlier.

Fund positioning in SER was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $104K. The largest seller was Millennium Management, cutting an estimated $27.8K.

  • 25 institutional investors held Serina Therapeutics (SER) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $1.6M of Serina Therapeutics stock for Q4 2024, down 20% quarter-over-quarter.
  • 2 funds opened new Serina Therapeutics positions in Q4 2024 and 2 closed out, a net change of 0 holders.
  • The largest Serina Therapeutics buyer in Q4 2024 was Vanguard Group, an estimated $104K added.
  • The largest Serina Therapeutics seller in Q4 2024 was Millennium Management, an estimated $27.8K sold.

Based on aggregated 13F filings for Q4 2024.